Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
NPJ Precision Oncology|January 11, 2025
Comprehensive analysis of targetable mutations and tumor microenvironment in urachal cancerDavid J Benjamin, Tolulope T Adeyelu, Andrew Elliott, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 15, 2025
Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint InhibitorsYusra F Shao, Yasmine Baca, Andrew Hinton, et al.Journal of the American College of Surgeons|April 23, 2024
Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted TherapySourat Darabi, Tolulope Adeyelu, Andrew Elliott, et al.Molecular Genetics & Genomic Medicine|March 23, 2019
Clinical validity assessment of genes for inclusion in multi-gene panel testing: A systematic approachTricia N Zion, Bess Wayburn, Sourat Darabi, et al.Medical Oncology (Northwood, London, England)|June 8, 2023
Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic targetSourat Darabi, Joanne Xiu, Timothy Samec, et al.Neuro-Oncology Advances|November 18, 2024
Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomasSonikpreet Aulakh, Joanne Xiu, Andrew Hinton, et al.Cancers|December 24, 2021
Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival OutcomesHira Shaikh, Julie E McGrath, Brittany Hughes, et al.Cancers|November 13, 2025
Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell CarcinomaPoorva Vaidya, Sharon Wu, Dave Bryant, et al.Human Mutation|January 21, 2017
Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and ReclassificationsErica D Smith, Kelly Radtke, Mari Rossi, et al.Medicina (Kaunas, Lithuania)|December 23, 2022
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum AgentsSourat Darabi, David R Braxton, Joanne Xiu, et al.Pageof 4